2023-505237-27-00
Completed
Phase 1
Bioequivalence clinical trial of two formulations of sacubitril/valsartan
Laboratorios Normon S.A.1 site in 1 country36 target enrollmentStarted: May 24, 2023Last updated:
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Laboratorios Normon S.A.
- Enrollment
- 36
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Carlos Govantes (R&D Director)
Scientific
Laboratorios Normon S.A.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Bioequivalence clinical trial of two formulations of linagliptin/metformin2024-515076-13-00Laboratorios Normon S.A.48
Completed
Phase 1
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin2023-507226-16-00Laboratorios Normon S.A.36
Completed
Phase 1
Bioequivalence clinical trial of two formulations of hydrochlorothiazide.2023-505692-72-00Laboratorios Normon S.A.30
Completed
Phase 1
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin2024-520303-62-00Laboratorios Normon S.A.36
Recruiting
Phase 1
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy AdultsNCT07261371Pfizer64